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Hypoxia-inducible factor 2-alpha-dependent
induction of amphiregulin dampens myocardial
ischemia-reperfusion injury
Michael Koeppen1,2, Jae W. Lee3, Seong-Wook Seo4, Kelley S. Brodsky5, Simone Kreth2, Ivana V. Yang6,
Peter M. Buttrick5, Tobias Eckle7 & Holger K. Eltzschig3
Myocardial ischemia–reperfusion injury (IRI) leads to the stabilization of the transcription
factors hypoxia-inducible factor 1-alpha (HIF1-alpha) and hypoxia-inducible factor 2-alpha
(HIF2-alpha). While previous studies implicate HIF1-alpha in cardioprotection, the role of
HIF2-alpha remains elusive. Here we show that HIF2-alpha induces the epithelial growth
factor amphiregulin (AREG) to elicit cardioprotection in myocardial IRI. Comparing mice with
inducible deletion of Hif1a or Hif2a in cardiac myocytes, we show that loss of Hif2-alpha
increases infarct sizes. Microarray studies in genetic models or cultured human cardiac
myocytes implicate HIF2-alpha in the myocardial induction of AREG. Likewise, AREG
increases in myocardial tissues from patients with ischemic heart disease. Areg deﬁciency
increases myocardial IRI, as does pharmacologic inhibition of Areg signaling. In contrast,
treatment with recombinant Areg provides cardioprotection and reconstitutes mice with
Hif2a deletion. These studies indicate that HIF2-alpha induces myocardial AREG expression in
cardiac myocytes, which increases myocardial ischemia tolerance.
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Myocardial infarction is among the leading causes ofdeath in the Western countries1. It results from theocclusion of a coronary artery by an intracoronary
thrombus, thereby preventing blood ﬂow to the metabolically
highly active myocardium. The mainstay therapy for acute
myocardial ischemia currently focuses on timely reperfusion—for
example by placement of an intracoronary stent1–4. However,
additional therapeutic approaches that render the myocardium
more resistant to ischemia are an important area of investigation.
Such approaches would contribute to the preservation of
myocardium at risk and could potentially improve outcomes
of patients suffering acute myocardial ischemia3,5,6.
During myocardial ischemia, the supply and demand ratio for
metabolites shifts dramatically—in particular for oxygen—
thereby causing profound tissue hypoxia2,7. Cellular responses to
hypoxia lead to stabilization of hypoxia-dependent transcription
factors8–10. Indeed, previous studies have suggested the
transcription factor hypoxia-inducible transcription factors
(HIFs) in cardio-adaptive responses. For example, HIFs mediate
the cardioprotective response induced by ischemic pre-
conditioning, where short time periods of ischemia treatment
reduces myocardial infarct sizes. During ischemic precondition-
ing HIFs are stabilized11, however, mice with partial deletion of
Hif1a are not protected by ischemic preconditioning12.
Similarly, HIFs have been implicated in mediating
cardioprotection provided by remote ischemic preconditioning, a
cardioprotective strategy where treatment of a limb for short time
periods of ischemia results in attenuated myocardial infarct
sizes5,13.
Due to their high metabolic demand, the functional role of
myocytes in cardio-adaptive responses during ischemia has been
the focus of many studies4,14, and several have indirectly
suggested myocardial-expressed HIFs in cardioprotection14.
However, a signiﬁcant obstacle for the systematic investigation of
HIFs in cardioprotection results from the fact that mice with
homozygous deletions of HIFs die early during embryogen-
esis2,15,16. To overcome this problem, we generated mice with
inducible myocyte-speciﬁc deletion of Hif1a or Hif2a, the two
predominant isoforms of HIFs that mediate alteration in genetic
programs during inﬂammatory or ischemic conditions17–19. For
this purpose, we crossed transgenic mice with a ﬂoxed Hif1a or
Hif2a gene with mice expressing Cre-recombinase under the
control of a tamoxifen-inducible myocyte-speciﬁc promoter
(Hif1aloxP/loxP Myosin-Cre+ and Hif2aloxP/loxP Myosin-Cre+
mice, respectively).
Exposure of these two mouse strains to IRI revealed a
previously unappreciated role in cardioprotection for myocyte-
dependent Hif2-alpha via induction of the growth factor
amphiregulin (Areg).
Results
Myocyte-speciﬁc Hif2a deletion enhances myocardial IRI.
Based on previous studies implicating HIFs in organ-protection
during ischemia and reperfusion injury2,7, we hypothesized that
myocyte-speciﬁc HIFs dampen myocardial ischemia and reper-
fusion injury. To overcome the problem that mice with a global
Hif1a or Hif2a deletion die during embryogenesis20, we generated
mice with induced deletion of Hif1a or Hif2a in cardiac myocytes.
To achieve this, we crossed Hif1aloxP/loxP or Hif2aloxP/loxP mice
with mice expressing tamoxifen-inducible Cre-recombinase
under the Myosin-heavy chain promoter (Myosin-Cre+)21. To
induce a Hif1a or Hif2a deletion, respectively, we treated these
mice with daily tamoxifen injections for 5 days (1 mg i.p./day),
followed by a 7 day recovery period (Fig. 1a). Subsequently, we
exposed the mice to in situ myocardial ischemia–reperfusion.
Western blot studies for Hif1-alpha or Hif2-alpha showed that
protein levels increased following 60 min of ischemia and 120 min
of reperfusion in Myosin-Cre+ mice. In contrast, the respective
HIF-isoform in the post-ischemic myocardium decreased notably
in Hif1a- or Hif2a-deﬁcient animals (Fig. 1b–d; Supplementary
Fig. 1). These ﬁndings demonstrate an increase of Hif1-alpha and
Hif2-alpha levels following myocardial ischemia and reperfusion
injury, while in genetic models for Hif1a or Hif2a deletion this
response is attenuated. These ﬁndings suggest that the mouse
lines generated allow us to assess the individual function of
myocyte-speciﬁc Hif1-alpha versus Hif2-alpha during myocardial
ischemia and reperfusion injury.
To assess the functional role of cardiac myocyte-speciﬁc Hif1-
alpha or Hif2-alpha in cardioprotection, we exposed Hif1aloxP/loxP
Myosin-Cre+ of Hif2aloxP/loxP Myosin-Cre+ mice to myocardial
ischemia and reperfusion injury and measured myocardial injury
by infarct size area or serum troponin levels. Surprisingly, we
found the predominant phenotype in Hif2aloxP/loxP Myosin-Cre+
mice. Indeed, mice with induced Hif2a deletion in cardiac
myocytes experienced dramatic increases in myocardial injury
when compared to Hif1aloxP/loxP Myosin-Cre+ mice or Myosin-
Cre+ controls (Fig. 1e–g). Together, these studies suggest a role
for myocyte-speciﬁc Hif2-alpha in cardioprotection during
ischemia and reperfusion injury.
Identiﬁcation of Areg as Hif2-alpha target during IRI. After
having shown that mice with induced Hif2a deletion in cardiac
myocytes experience increased myocardial injury, we next inves-
tigated a transcriptional mechanism that could elicit Hif2a-
dependent cardioprotection. Previous studies implied Hif1-alpha
in cardioprotection from ischemia12–14. In contrast, a functional
role of Hif2-alpha in cardioprotection is largely unknown. Since
HIFs mediate adaptive responses through the induction of target
genes, we performed a microarray study comparing transcript
levels of the post-ischemic myocardium from Myosin-Cre+ or
Hif2aloxP/loxP Myosin-Cre+ mice. Consistent with a role of
myocyte-speciﬁc Hif2-alpha as a transcriptional inducer, we iden-
tiﬁed a set of genes that increased in the post-ischemic myo-
cardium of Myosin-Cre+ but not in Hif2aloxP/loxPMyosin-Cre+
mice. Among transcript levels upregulated in an Hif2-alpha-
dependent fashion, the strongest differentially regulated
transcript was the epithelial growth factor Amphiregulin (Areg)
(Fig. 2a, b). To follow-up on the ﬁndings from the microarray
study, we examined Areg transcript and protein levels in the
area-at-risk (AAR) of Hif1aloxP/loxP Myosin-Cre+, Hif2aloxP/loxP
Myosin-Cre+, or Myosin-Cre+ mice. Consistent with our ﬁndings
in the microarray, we observed that Areg transcript and protein
levels signiﬁcantly increased in Myosin-Cre+ and mice with
cardiomyocyte-speciﬁc Hif1a deﬁciency. In contrast, the
induction of Areg in post-ischemic myocardial tissues was
signiﬁcantly attenuated in Hif2aloxP/loxP Myosin-Cre+ mice
(Fig. 2c–e; Supplementary Fig. 2). Together with previous studies
from the cancer ﬁeld suggesting that Hif2-alpha binds to the Areg
promoter and induces its transcription22,23 our ﬁndings indicate
that Hif2-alpha transcriptionally induces Areg during murine
myocardial IRI.
HIF2-alpha regulates AREG expression in human cardiac
myocytes. Based on the ﬁndings that Hif2-alpha regulated Areg
transcript and protein levels in a murine in vivo model of
myocardial ischemia and reperfusion injury, we next performed
studies in cultured human cardiomyocytes to demonstrate that
the observed changes in murine Areg levels also occur in human
myocardial tissues. Thus, we exposed human cardiac myocytes
(HCM) to hypoxia and measured AREG transcript and protein
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Fig. 1 Contribution of myocyte-speciﬁc hypoxia-inducible factor (HIF) isoforms Hif1a or Hif2a to cardioprotection. a Schematic of breeding approach
to generate mice with induced myocyte-speciﬁc HIF deletions used in subsequent studies. Hif1aloxP/loxP or Hif2aloxP/loxP mice were crossed with
Cre-recombinase expressing mice under the control of Myosin-heavy chain promoter (Myosin-Cre+); these mice express cre-recombinase under the
control of a tamoxifen-inducer. Control animals (Myosin-Cre+), Hif1aloxP/loxPMyosin-Cre+ or Hif2aloxP/loxPMyosin-Cre+ received a daily dose of 1 mg i.p.
Tamoxifen ﬁve consecutive days to induce the Cre-recombinase activity. After 7 days, animals underwent experimental protocol (60min of in situ
myocardial ischemia followed by 120min of reperfusion). b HIF1-alpha or HIF2-alpha immunoblot analysis from homogenized myocardial tissue, harvested
from male Myosin-Cre+ and Hif1aloxP/loxPMyosin-Cre+ or Hif2aloxP/loxPMyosin-Cre+ mice, matched in age and weight. Mice underwent a thoracotomy with no
further treatment(-I) or 60min of myocardial ischemia (+I) followed by 120min reperfusion; β-Actin (ACTb) served as a loading control. One
representative blot out of three experiments is shown. c, d Quantiﬁcation by densitometry of the HIF-immunoblot results relative to ACTb. Data are
expressed as mean fold change ±SD normalized to untreated myocardial tissue from Myosin-Cre+ compared by one-way ANOVA followed by Bonferroni’s
multiple comparison test (n= 3 per group; c: F5,12= 6.74, p= 0.0033; d: F5,12= 21.85, p< 0.0001). e Infarct sizes ±SD in Myosin-Cre+, Hif1aloxP/loxP
Myosin-Cre+ or Hif2aloxP/loxPMyosin-Cre+mice, presented as the percentage to the area-at-risk after 60min of ischemia, followed by 120min of reperfusion
(Myosin-Cre+ n= 5; Hif1aloxP/loxPMyosin-Cre+ n= 5; Hif2aloxP/loxPMyosin-Cre+ n= 4; per group mean± SD; compared by one-way ANOVA followed by
Bonferroni’s multiple comparison test; F2,11= 7.901; p= 0.0075). f Representative infarct staining from Myosin-Cre+, Hif1aloxP/loxPMyosin-Cre+ or
Hif2aloxP/loxPMyosin-Cre+. g Troponin serum levels after 60min ischemia, followed by 120min of reperfusion in Myosin-Cre+, Hif1aloxP/loxPMyosin-Cre+ or
Hif2aloxP/loxPMyosin-Cre+ (Myosin-Cre+ n= 5; Hif1aloxP/loxPMyosin-Cre+ n= 5, and Hif2aloxP/loxPMyosin-Cre+ n= 4 per group; presented as mean± SD;
compared by one-way ANOVA followed by Bonferroni’s multiple comparison test; F2,11= 19.14, p= 0.0003)
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levels. To address a functional role for HIF2-alpha in AREG
induction, we generated HCM cells lines with stable lentiviral-
mediated shRNA-mediated repression of HIF1-alpha or HIF2-
alpha. Indeed, lentiviral-mediated shRNA transduction in HCM
repressed HIF1-alpha or HIF2-alpha transcript levels at baseline
(Fig. 3a, b). To examine if the lentiviral-mediated shRNA
repression of HIF1-alpha or HIF2-alpha also attenuated HIF
protein stabilization during hypoxia, we exposed control-
transduced HCMs, or HCMs transduced with lentiviral shRNA
targeting HIF1-alpha or HIF2-alpha to ambient hypoxia (1%
oxygen for 16 h). While exposure of control cells to ambient
hypoxia stabilized HIF1-alpha and HIF2-alpha protein, these
responses were abolished in HCM cell lines with corresponding
shRNA-mediated HIF repression (Fig. 3c–e). Together, these
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Fig. 2 Hif2a-dependent induction of amphiregulin during myocardial injury. a, b Myosin-Cre+ or Hif2aloxP/loxPMyosin-Cre+ underwent 45min myocardial
ischemia, followed by 120min reperfusion. After harvest of the area-at-risk, total RNA was probed for transcriptional changes using a microarray technique
(Agilent-014868 Whole Mouse Genome Microarray 4x44K G4122F Probe Name version). Transcriptional changes were calculated in relation to the
myocardial baseline expression in untreated littermate controls of the same genotype. Array data have been deposited at http://www.ncbi.nlm.nih.gov/
geo/ (accession number GSE67308). a List of “top hits” of genes transcriptionally induced in the Area-At-Risk in Myosin-Cre+ but unchanged in Hif2aloxP/
loxPMyosin-Cre+ (n= 4 per group, mean± SD). Note: the most prominent differential regulation was found for the epidermal growth factor amphiregulin
(Areg). b Analysis of relevant networks in the IPA (Ingenuity Pathway Analysis®) library most signiﬁcant to the dataset. Note: selective induction of Areg c
Myosin-Cre+, Hif1aloxP/loxPMyosin-Cre+, or Hif2aloxP/loxPMyosin-Cre+ underwent 60min myocardial ischemia, following 120min reperfusion. Total RNA from
the area-at-risk was probed for transcriptional changes of Areg by real-time RT-PCR. Transcriptional changes were calculated relative to an internal
housekeeping gene (Actb). Data are expressed as mean fold change± SD compared to untreated myocardial tissue from littermates of the respective
genotype compared by one-way ANOVA followed by Bonferroni’s multiple comparison test (Myosin-Cre+: −I n= 6, +I n= 5; Hif1aloxP/loxPMyosin-Cre+: −I n= 3;
+I n= 4; Hif2aloxP/loxPMyosin-Cre+: −I n= 6; +I n= 7; F5,25= 33.53; p< 0.0001). d AREG immunoblot performed for protein isolated from the ischemic
myocardial tissue after 60min of ischemia and 120min reperfusion or untreated littermate controls of Myosin-Cre+, Hif1aloxP/loxPMyosin-Cre+ or
Hif2aloxP/loxPMyosin-Cre+, respectively. A representative image of three individual experiments is presented. e Quantiﬁcation by densitometry of the AREG
immunoblot results relative to ACTb. Data are expressed as mean fold change± SD normalized to untreated myocardial tissue fromMyosin-Cre+ compared
by one-way ANOVA followed by Bonferroni’s multiple comparison test (n= 3 per group; F5,12= 4.487; p= 0.0154)
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studies indicate that these human myocyte cell lines can be used
to study differential roles for HIF1-alpha- or HIF2-alpha-
dependent gene induction during hypoxia. Indeed, induction of
AREG transcript and protein levels remained intact in HCM
transduced with control or HIF1-alpha-repressing shRNA, but
were entirely abolished following shRNA-mediated repression of
HIF2-alpha (Fig. 3f–h; Supplementary Fig. 3). Taken together,
these ﬁndings demonstrate that HIF2-alpha is a transcriptional
driver of AREG in HCM.
AREG levels increase in patients with ischemic heart disease.
After having shown that Areg levels increased in a murine
myocardial ischemia and reperfusion injury model or in HCM
exposed to hypoxia, we next performed proof-of-principle studies
to examine AREG levels in cardiac tissues obtained from healthy
controls or patients with ischemic heart disease (IHD). We
received these cardiac tissues from a human biobank that stores
human heart samples14. Cardiac tissues from IHD patients were
retrieved from explanted hearts during cardiac transplantation.
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Fig. 3 Functional role of HIF2A in the transcriptional regulation of amphiregulin (AREG) in human cardiac myocytes. a–e Human cardiac myocytes (HCM)
underwent control, HIF1A-speciﬁc or HIF2a-speciﬁc short hairpin RNA (shRNA) lentiviral transfection to suppress transcription of hypoxia-inducible factors
HIF1A or HIF2A. a, b shRNA-transfected HCM were exposed to ambient hypoxia (1% oxygen) for 16 h and analysis of transcript changes by RT-PCR of
HIF1A or HIF2A, respectively. Transcriptional changes were calculated relative to an internal housekeeping gene (Actin-b). Data are expressed as mean
fold change± SD compared to normoxic cells (n= 6 per group). c Immunoblot for HIF1A or HIF2A from shRNA-transfected normoxic or hypoxic HCM. β-
Actin (ACTb) served as a loading control. d, e Quantiﬁcation by densitometry of the HIF1-alpha or HIF2-alpha immunoblot results relative to ACTb. Data
are expressed as mean fold change± SD normalized to shControl compared by one-way ANOVA followed by Bonferroni’s multiple comparison test (n= 3
per group; d F5,11= 14.48, p= 0.0002; e F5,11= 6,726, p= 0.0042). f HCM transfected with shRNA directed against HIF1A, HIF2A or control shRNA were
exposed to ambient hypoxia (1% oxygen) for 16 h or were maintained under normoxic conditions (21% oxygen). Subsequently, total RNA was isolated and
probed by RT-PCR for transcriptional changes of amphiregulin (AREG). Data are expressed as mean fold change± SD compared to normoxic cells (n= 3
per group). Transcriptional changes were calculated relative to an internal housekeeping gene (ACTb). Data compared by one-way ANOVA followed by
Bonferroni’s multiple comparison test (F5,12= 14.33; p= 0.0001). g HCM transfected with shRNA directed against HIF1A, HIF2A, or control shRNA, total
protein was isolated and immunoblotted for AREG. b-Actin (Actb) served as a loading control. One representative blot out of three experiments is shown. h
Quantiﬁcation by densitometry of the HIF immunoblot results relative to ACTb. Data are expressed as mean fold change± SD normalized to normoxic cells
(shControl) and compared by one-way ANOVA followed by Bonferroni’s multiple comparison test (n= 3 per group; F5,12= 11, 58; p= 0.0003)
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Cardiac tissues that served as healthy controls were taken from
donor hearts that were deemed sufﬁcient as a cardiac allograft,
but could not be used for transplantation due to logistic reasons.
Consistent with a functional role for myocardial ischemia in
AREG induction, AREG protein levels were elevated in patients
with IHD compared to healthy controls (Fig. 4a, b; Supplemen-
tary Fig. 4). Taken together, these proof-of-principle studies
indicate that AREG expression increased in cardiac tissues from
patients experiencing myocardial ischemia.
Areg deﬁciency is associated with enlarged infarct sizes. After
having shown that murine and human myocardial AREG levels
increased during conditions of limited oxygen availability via
transcriptional control by HIF2-alpha, we addressed the func-
tional role of AREG during IRI. Since mice with induced Hif2a
deletion in cardiac myocytes experienced larger myocardial
injury, we anticipated a cardioprotective role of Areg. To address
this hypothesis, we performed studies in previously described
mice gene-targeted for Areg24. Exposure of Areg−/− mice to 60
min of myocardial ischemia followed by 120 min of reperfusion
revealed larger infarct sizes and elevated levels of the myocardial
necrosis marker troponin I (Fig. 5a–c). Moreover, reconstitution
of Areg−/−mice via intravascular infusion of murine recombinant
Areg reduced ischemic myocardial tissue injury, including smaller
infarct sizes (Fig. 5d, e) and attenuated release of troponin I
(Fig. 5f). Together, these ﬁndings suggest that genetic deletion of
Areg increases myocardial tissue injury following murine ische-
mia and reperfusion injury, while reconstitution with 10 µg
recombinant Areg can rescue the phenotype of Areg−/− mice.
Blockade of ErbB1 signaling increases myocardial injury. Since
genetic deletion of Areg profoundly increased myocardial injury,
we performed pharmacologic studies in wild-type mice targeting
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Fig. 5 Myocardial tissue injury in Areg−/− mice exposed to myocardial
ischemia and reperfusion injury. a–f Experimental animals were exposed to
60min of myocardial ischemia, followed by 120min of reperfusion; infarct
sizes were measured by double staining with Evan’s blue and
triphenyltetrazolium chloride and serum samples were collected. All infarct
sizes are presented as the percentage of infarcted tissue in relation to the
area-at-risk. Serum troponin levels were determined by ELISA (a). Infarct
sizes were determined in gene-targeted mice for amphiregulin (Areg−/−
mice) or isogenic control animals (Areg+/+ mice) (n= 5 per group). b
Representative infarct staining from Areg−/− or Areg+/+. c Troponin serum
levels in Areg−/− or Areg+/+ mice (n= 5 per group). d Reconstitution of
Areg−/− mice with recombinant AREG. Infarct sizes in Areg−/− treated with
vehicle or 10 μg of recombinant murine Areg, administered over 15min
period by an indwelling catheter (n= 6 per group). e Representative infarct
staining from Areg−/− mice treated with vehicle or 10 µg recombinant
murine Areg. f Troponin serum levels after myocardial IR injury of Areg−/−
mice treated with vehicle or 10 µg recombinant murine Areg via an
intraarterial catheter over a 15min period (n= 7 per group). All data
presented as mean± SD. Statistical signiﬁcance assessed by two-sided,
unpaired Student’s t-test
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the Areg receptor ErbB1. Indeed, cardiac tissues express receptors
for epidermal growth factors (ErbB receptors), which play
important roles in cardiac development25. ErbB1 is expressed on
cardiac myocytes, but undetectable on vascular endothelia26 and
previous studies demonstrate that AREG solely binds and signals
through the ErbB127. Based on these studies, we hypothesized
that AREG elicits its cardioprotective effects via activation of the
ErbB1 receptor. To address this hypothesis, we performed myo-
cardial ischemia and reperfusion injury in the presence of the
pharmacologic ErbB1 receptor antagonist AG147828. Mice
received 20 mmol/kg of AG1478 or vehicle 30 min prior to
myocardial ischemia, given as slow infusion via a catheter placed
into the carotid artery. Subsequently, mice underwent 60 min of
myocardial ischemia and 120 min of reperfusion. Consistent with
a functional role for AREG in cardioprotection, treatment with
the ErbB1 receptor antagonist AG1478 increased myocardial
infarct sizes and signiﬁcantly elevated serum troponin levels
(Fig. 6a–c)—a phenotype similar to the ﬁndings in Hif2aloxP/loxP
Myosin-Cre+ or Areg−/− mice. Together these ﬁndings indicate
that AREG-dependent signaling events through the ErbB1
receptor promote cardioprotection from acute myocardial ische-
mia and reperfusion injury.
Inhibition of ErbB1-ligand binding increases infarct sizes. As
next step, we sought to conﬁrm the above ﬁndings with the
pharmacologic ErbB1 inhibitor AG1478 utilizing a more speciﬁc
approach for the ErB1 receptor. For this purpose, we used the
recombinant, monoclonal antibody cetuximab, which binds solely
to the extracellular domain of the ErbB1. Binding of cetuximab to
ErbB1 completely inhibits binding of the natural ligand and
activation of the receptor signaling cascade29–32. For the purpose
of this study, mice received 20 mg/kg of cetuximab or vehicle 15
min prior to myocardial ischemia, given as slow infusion via a
carotid artery catheter. Subsequently, mice were submitted to 60
min of myocardial ischemia followed by 120 min of reperfusion.
Consistent with the effect of pharmacological inhibition of ErbB1
utilizing AG1478, treatment with the anti-ErbB1 antibody
cetuximab was associated with increased myocardial infarct sizes
and signiﬁcantly elevated serum troponin levels (Fig. 6d–f).
Together these ﬁndings indicate that ErbB1 signaling events
promote cardioprotection from acute myocardial ischemia and
reperfusion injury.
Recombinant Areg treatment dampens murine IRI. Based on
our studies in mice with induced Hif2a deletion in cardiac
myocytes or studies in mice with global Areg deletion, we
hypothesized that treatment with recombinant murine Areg
could provide cardioprotection from ischemia and reperfusion
injury. We used a treatment regime consistent of 10 µg recom-
binant Areg given as a slow infusion via a catheter placed into the
carotid artery 15 min prior to the onset of myocardial ischemia.
Control mice received a similar infusion with vehicle. Subsequent
exposure to 60 min of myocardial ischemia followed by 120 min
of reperfusion was associated with signiﬁcantly reduced myo-
cardial infarct sizes and troponin I serum levels compared to
vehicle treated mice (Fig. 7a–c; Supplementary Fig. 5).
Next, we investigated whether intraarterial administration of
recombinant murine Areg increases myocardial Areg protein
levels. For this purpose, we treated mice with recombinant Areg
and submitted them to our model of myocardial ischemia and
reperfusion injury. As controls we used Areg+/+ or Areg−/−
animals receiving vehicle infusion. After 120 min of reperfusion,
we identiﬁed the AAR by Evans blue counterstain technique and
immunoblotted for murine Areg protein. Myocardial ischemia
and reperfusion alone increased myocardial Areg levels (Fig. 7d,
Areg+/+ +Vehicle). Treatment with recombinant murine Areg
was associated with dramatically increased Areg protein levels in
wild-type or in Areg−/− mice (Fig. 7d, upper panel and Fig. 7e).
Together, these ﬁndings conﬁrm that exogenous administration
of recombinant Areg leads to elevated Areg protein levels in the
myocardium, and provides a rational for the therapeutic effects
observed following treatment with recombinant Areg.
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Fig. 6 Pharmacologic inhibition of the amphiregulin receptor ErbB1 during
murine myocardial ischemia–reperfusion injury. a–c Mice underwent 60
min of myocardial ischemia, followed by 120min of reperfusion; infarct
sizes were measured by double staining with Evan’s blue and
triphenyltetrazolium chloride and serum samples were collected. All infarct
sizes are presented as the percentage of infarcted tissue in relation to the
area-at-risk. Serum Troponin levels were determined by ELISA. a Infarct
sizes of C57/BL6 mice after 60min of ischemia and 120min reperfusion,
treated prior to myocardial ischemia reperfusion with vehicle or an ERBB1-
speciﬁc inhibitor (AG1478), administered 15 min prior to ischemia via an
indwelling arterial catheter. Data presented as the percentage of infarcted
area in relation to area-at-risk (n= 4 per group). b Representative infarct
staining of C57/BL6 treated with vehicle or AG1478. c Troponin serum
levels of C57/BL6 mice, after 60min ischemia, 120min reperfusion, treated
with vehicle or AG1478 (n= 5 per group). d Infarct sizes of C57/BL6 mice
after 60min of ischemia and 120min reperfusion, treated 15min prior to
ischemia via an indwelling arterial catheter with vehicle or a highly speciﬁc
ERBB1-speciﬁc inhibitor (Cetuximab). Data presented as the percentage of
infarcted area in relation to area-at-risk (control n= 4; cetuximab n= 8). e
Representative infarct staining of C57/BL6 treated with vehicle or
Cetuximab. f Troponin serum levels of C57/BL6 mice after 60min
ischemia, 120min reperfusion, treated with vehicle or Cetuximab (n= 7 per
group). All data in this ﬁgure is presented as mean± SD. Statistical
signiﬁcance assessed by two-sided, unpaired Student’s t-test
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After having shown that treatment with recombinant Areg
reduced myocardial injury following ischemia and reperfusion,
we next investigated whether administration of recombinant
murine Areg activates cardioprotective pathway, e.g. via activa-
tion of survival kinases such as Akt33. As described above, we
treated Areg+/+ and Areg−/− mice with recombinant Areg, and
immunoblotted for Akt (tAkt) and the activated form (phos-
phorylated Akt; pAkt). As shown in Fig. 7d, Areg deﬁciency
coincides with reduced levels of pAkt after ischemia and
reperfusion. Reconstitution of Areg−/− mice with recombinant
protein normalized pAkt after ischemia reperfusion (Fig. 7d,
lower panel and Fig. 7f). This indicates that myocardial levels of
AREG expression correlate with activation of survival kinases—
such as pAkt—which provides some insight into a potential
mechanism for AREG-dependent cardioprotection.
Areg treatment reconstitutes Hif2a-deﬁcient mice. Next, we
investigated whether reconstitution with recombinant Areg
rescues the phenotype of mice with cardiomyocyte-speciﬁc
Hif2a deﬁciency. For this purpose, we treated Hif2aloxP/loxP
Myosin-Cre+ mice with 10 µg recombinant Areg given as a slow
infusion via a catheter placed into the carotid artery 15 min prior
to the onset of myocardial ischemia. Myocardial injury and serum
troponin levels after subsequent exposure to 60 min ischemia and
120 min of reperfusion was signiﬁcantly reduced in comparison
to control mice (Fig. 8a–c).
Based on the above studies showing that Areg deﬁciency is
associated with reduced activation of the survival kinase Akt after
myocardial ischemia and reperfusion, we harvested the AAR form
Hif2aloxP/loxP Myosin-Cre+ and immunoblotted the isolated
protein for total levels Akt and phosphorylated Akt. Consistent
with our ﬁndings in Areg−/− mice, we observed that Hif2a
deﬁciency in cardiomyocytes is associated with attenuated
Akt-phosphorylation in response to ischemia and reperfusion
(Fig. 8d, e; Supplementary Fig. 6). In line with previous studies
showing cardioprotection via Akt-phosphorylation33, these ﬁnd-
ings indicate the possibility that Hif2-stabilization could mediate
cardioprotection via increased activation of Akt through elevating
cardiac Areg signaling. Taken together, the above studies indicate
that treatment with recombinant Areg is associated with
normalized susceptibility of Hif2aloxP/loxP Myosin-Cre+ mice to
ischemic myocardial injury and provide further evidence for a
Hif2-alpha-dependent Areg induction in cardioprotection.
Discussion
In the present studies, we address the functional roles of HIFs in
mediating cardioprotective responses through the induction of
speciﬁc gene products. As mice with global deletion of HIFs are
not viable34–36, we generated mice with inducible deletion of
Hif1a or Hif2a in cardiac myocytes. Ischemic tissue injury was
similar in Myosin-Cre+ and Hif1aloxP/loxPMyosin-Cre+ mice,
while we uncovered a profound phenotype in Hif2aloxP/loxP-
Myosin-Cre+ mice, including an almost 64% increase of infarct
sizes and dramatically elevated serum troponin levels. These data
indicate a surprising role for myocyte-speciﬁc Hif2a in cardio-
protection from ischemia. In order to identify potential target
genes that could mediate the cardioprotective role of Hif2a, we
performed a microarray study comparing ischemic cardiac tissues
from controls or mice with cardiac myocyte-speciﬁc deletion of
Hif2a. The dominant read-out of this array and conﬁrmatory
studies identiﬁed an Hif2a-speciﬁc induction of the epidermal
growth factor Areg during myocardial ischemia. Indeed, AREG
expression was also elevated in cardiac tissues samples of patients
with ischemic heart disease. In addition, pharmacologic studies
utilizing inhibitors of AREG signaling (AG1478 or cetuximab
treatment) showed increased myocardial injury. Moreover,
myocardial tissue injury increased in mice with genetic deletion of
Areg, while treatment of wild-type mice with recombinant Areg
attenuated myocardial tissue injury. Finally, reconstitution of
Hif2aloxP/loxP Myosin-Cre+ mice with recombinant Areg rescued
their phenotype. Based on these ﬁndings we conclude that HIF2-
60
40
20
60
40
20 T
ro
po
ni
n 
I [n
g/m
l]
In
fa
rc
t s
ize
 [%
are
a a
t ri
sk
]
Fo
ld
 c
ha
ng
e 
AR
EG
/A
CT
b
Fo
ld
 c
ha
ng
e 
pA
KT
/tA
KT
C57/BL6
(kDa)
50
37
50
50
C57/BL6
3
2
1
0
3
2
1
0
p<0.05
P < 0.05p<0.05
p<0.05
p<0.05
p<0.05
Ar
eg
+
/+
Ar
eg
–
/–
Ar
eg
–
/–
Ar
eg
+
/+
Vehicle
10 µg AREG
Areg+/+ +
10 µg AREG
Areg+/+ +
vehicle
Areg–/– +
10 µg AREG
Areg–/– +
vehicle
Vehicle 10 µg AREG
pAKT
Areg
Actb
tAKT
a b c
d e f
Fig. 7 Treatment of murine myocardial ischemia and reperfusion injury with
recombinant amphiregulin. a–c Wild-type were exposed to 60min of
myocardial ischemia, followed by 120min of reperfusion; infarct sizes were
measured by double staining with Evan’s blue and triphenyltetrazolium
chloride and serum samples were collected. All Infarct sizes are presented
as the percentage of infarcted tissue in relation to the area-at-risk. Serum
troponin levels were determined by ELISA. a Infarct sizes of C57/BL6 mice
after 60min of ischemia and 120min reperfusion, treated with vehicle or
10 µg recombinant murine AREG, administered over a 15min period via an
indwelling arterial catheter. Data presented are the percentage of infarcted
area in relation to area-at-risk. Statistical signiﬁcance assessed by two-
sided, unpaired Student’s t-test (n= 7 per group; data presented as mean±
SD). b Representative infarct staining of C57/BL6 treated with vehicle or
10 µg recombinant murine AREG. c Serum troponin levels of C57/BL6 mice,
after 60min ischemia, 120 min reperfusion, treated with vehicle or 10 µg
recombinant murine Areg. Statistical signiﬁcance assessed by two-sided,
unpaired Student’s t-test (n= 5 per group; data presented as mean± SD). d
Areg+/+ or Areg−/− mice received treatment with vehicle or 10 μg of
recombinant murine AREG, administered over a 15 min period by an
indwelling catheter. The animals underwent 60min ischemia and 120min
reperfusion, followed by total protein isolation form the area-at-risk. Upper
panel: protein was immunoblotted for AREG, β-actin (ACTb) served as a
loading control. Lower panel: protein was immunoblotted for total AKT
(tAKT) and phosphorylated AKT (pAKT), respectively. Two samples for
each condition and genotype are presented. One representative blot out of
three experiments is shown. e, f Quantiﬁcation by densitometry of the
AREG and pAKT immunoblot results relative to ACTb or Total AKT (tAKT).
Data are expressed as mean fold change± SD normalized to vehicle treated
Areg+/+ and compared by one-way ANOVA followed by Bonferroni’s
multiple comparison test (Areg+/++Vehicle n= 5; all other groups n= 6
mice per group, e F3,19= 23,11, p< 0.0001; f F3,20= 9,549, p= 0.0002)
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alpha coordinates the induction of AREG in cardiac myocytes,
and thereby conveys potent cardioprotection from myocardial
ischemia and reperfusion injury.
In line with the present studies, others have shown a functional
role of HIFs in cardioprotection during ischemia and reperfusion
injury. For example, inhibition of HIF-degradation provides
strong protection from ischemia and reperfusion injury by var-
ious mechanisms37,38. One study examined the functional role of
prolyl-hydroxylase enzymes (PHD), which control the stabiliza-
tion of HIFs39. In this study the authors demonstrated that Phd1-
deﬁcient mice experienced higher levels of Hif1-alpha and con-
comitant cardioprotection from ischemia and reperfusion injury.
Furthermore, loss of function of PHD2 protects from ischemia
and reperfusion injury40 and improves cardiac function weeks
after ischemia41 due to an increase of Hif1-alpha and Hif2-alpha.
Cardioprotective strategies, such as remote preconditioning
and ischemic preconditioning, also rely on a stabilization of
HIF1-alpha12,13. Interestingly, in the present study we show that
though HIF1-alpha activity is induced by a single ischemia
reperfusion episode (without preconditioning), this activation is
not enough to promote cardioprotection. Therefore, HIF1-alpha
only confers cardioprotection in ischemic preconditioning set-
tings but not after a single episode of ischemia and reperfusion.
This could be related to temporal or tissue-speciﬁc issues. For
example, it is conceivable that HIF1-alpha stabilization to provide
cardioprotection may only be efﬁcient when it occurs prior to the
insult. Alternatively, it is conceivable that HIF1-alpha stabiliza-
tion may occur in the whole heart—particularly the myocyte
compartment—however, HIF1-alpha-dependent cardioprotec-
tion through ischemic preconditioning may involve different
tissue compartments of the heart—such as the myeloid com-
partment or endothelial cell. Interestingly, a recent study found
that vascular-endothelial Hif1a mediates the acute phase of car-
dioprotection by ischemic preconditioning42, whereas our pre-
vious study suggest that HIF1-alpha is essential for the protective
effects of ischemic preconditioning14. In contrast to this, ischemic
preconditioning was preserved in mice with cardiomyocyte-
speciﬁc deletion of HIF2-alpha. This suggests that the axis HIF2-
alpha-AREG does not play a role in ischemic preconditioning.
Pharmacologic HIF activators can be used to imitate the cardi-
oprotective responses elicited by ischemic preconditioning11. In
contrast to this, HIF1-alpha in cardiomyocytes does not inﬂuence
myocardial injury in ischemia and reperfusion as shown in the
present study. This indicates that myocyte-mediated cardiopro-
tection through HIFs predominantly involves HIF2-alpha. Thus,
the present ﬁndings suggest that myocyte-speciﬁc HIF2-alpha
increases myocardial ischemia tolerance, which has not been
previously reported. Along these lines, studies in other organs
than the heart have implicated HIF2-alpha in organ protection
from ischemia and reperfusion injury, for example during
ischemia and reperfusion injury of the kidney17.
Our ﬁndings implicate myocyte-speciﬁc Hif2a in cardiopro-
tection from ischemia and reperfusion injury, whereas previous
studies have found a role for Hif1a in mediating cardioprotection
elicited by ischemic preconditioning11,12. Indeed, based on several
previous studies, it appears that HIF1-alpha is essential for car-
diac ischemic preconditioning.11,14 At ﬁrst look, these ﬁndings
appear to be in contrast with the present studies showing a car-
dioprotective role for HIF2-alpha as well. However, different
protocols (ischemic preconditioning versus ischemia and reper-
fusion injury) and different tissue compartments (e.g. vascular
compartment42 versus the myocyte compartment14) likely
account for functional differences of the HIF isoforms HIF1-
alpha and HIF2-alpha. Speciﬁcally, a previous study from the
laboratory of Dr. Semenza demonstrated that mice with hetero-
zygote deletion of Hif1a are not protected by ischemic
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Fig. 8 Reconstitution of cardiomyocyte-speciﬁc Hif2a-deﬁcient mice with
recombinant amphiregulin. a–c Hif2aloxP/loxPMyosin-Cre+ of similar age,
gender, and weight as control mice were exposed to 60min of myocardial
ischemia, followed by 120min of reperfusion; infarct sizes were measured
by double staining with Evan’s blue and triphenyltetrazolium chloride and
serum samples were collected. All Infarct sizes are presented as the
percentage of infarcted tissue in relation to the area-at-risk. Serum troponin
levels were determined by ELISA. Note that data in (a–c) in the “no
treatment group” are used in part in Fig. 1c–e to display and analyze IR
injury from similar experimental conditions. a Infarct sizes of Hif2aloxP/
loxPMyosin-Cre+ mice after 60min of ischemia and 120min reperfusion that
were pre-treated with 10 µg recombinant murine AREG administered over a
15 min period via an indwelling arterial catheter or received no
pharmacologic intervention. Data presented as the percentage of infarcted
area in relation to area-at-risk. Statistical signiﬁcance assessed by two-
sided, unpaired Student’s t-test (no treatment n= 6; 10 μg AREG n= 9, data
presented as mean± SD). b Representative infarct staining of Hif2aloxP/
loxPMyosin-Cre+ that were pre-treated with 10 µg recombinant murine Areg
administered over a 15 min period via an indwelling arterial catheter or
received no pharmacologic intervention. c Serum troponin levels of
Hif2aloxP/loxPMyosin-Cre+ mice, after 60min ischemia, 120min reperfusion
that were pre-treated with 10 µg recombinant murine AREG administered
over a 15 min period via an indwelling arterial catheter, or received no
pharmacologic intervention. Statistical signiﬁcance assessed by two-sided,
unpaired Student’s t-test (no treatment n= 4; 10 μg AREG n= 7, data
presented as mean± SD). d Hif2aloxP/loxPMyosin-Cre+ or Myosin-Cre+ mice
underwent 60min myocardial ischemia, followed by 120min of reperfusion.
Then the area-at-risk was excised, protein isolated and immunoblotted for
total AKT (tAKT) or phosphorylated Akt (pAKT). Two samples for each
condition and genotype are presented. One representative blot out of three
experiments is shown. e Quantiﬁcation by densitometry of pAKT
immunoblot results relative to total AKT (tAKT). Data are expressed as
mean fold change± SD normalized to Myosin-Cre+. Statistical signiﬁcance
assessed by two-sided, unpaired Student’s t-test (three individual blots
analyzed with n= 7 mice per group)
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preconditioning12. Similarly, other studies indicate that Hif1a
repression with siRNA prevents cardioprotection by ischemic
preconditioning. However, the role of HIF2-alpha in cardiopro-
tection has previously been unclear. To address the functional role
of Hif2a during myocardial ischemia and reperfusion injury, we
used genetic models and found that myocyte-speciﬁc Hif2a is
critical for the cardioprotection during ischemia and reperfusion
injury. To address the functional role of Hif2a in ischemic pre-
conditioning we performed additional studies. Here we found that
cardioprotection by ischemic preconditioning is intact in control
mice (Myosin-Cre+ mice) or Hif2aloxP/loxPMyosin-Cre+ mice,
whereas cardioprotection by ischemic preconditioning is abolished
in Hif1aloxP/loxPMyosin-Cre+ mice (Supplementary Fig. 7A–C).
Together, with previous studies, these ﬁndings indicate a somewhat
speciﬁc role for HIF1-alpha in mediating cardioprotective effects of
ischemic preconditioning11,42.
Previous studies on the role of HIF1-alpha found that the
cardioprotective effects of ischemic preconditioning can be
pharmacologically recapitulated utilizing the HIF activator
DMOG. Importantly, the PHD inhibitor DMOG will result in the
stabilization of both HIF isoforms—HIF1-alpha and HIF2-alpha
—in different cardiac tissue compartments, including the vascu-
lature and cardiac myocytes. To answer the question if DMOG-
elicited cardioprotection also involves HIF2-alpha, we performed
additional studies. Here, we found that the cardioprotective effect
of DMOG is intact in control mice (Myosin-Cre+ mice) but
attenuated in mice with myocyte-speciﬁc deletion of Hif2a
(Hif2aloxP/loxPMyosin-Cre+ mice; Supplementary Figure 8A, B).
Similarly, in mice with siRNA-mediated Hif1a repression,
DMOG-dependent cardioprotection was attenuated, as we had
reported previously11. Together, these ﬁndings indicate that
DMOG likely mediates cardioprotection via stabilization of both
HIF isoforms—HIF1-alpha and HIF2-alpha. Previous studies
suggest that HIF1-alpha-dependent cardioprotection involves
purinergic signaling events, particularly through the A2B ade-
nosine receptor11,14, whereas the current studies implicate AREG
signaling as a mediator of HIF2A-dependent cardioprotection.
This notion is also supported by the current ﬁndings that
Hif2aloxP/loxPMyosin-Cre+ mice can be rescued via treatment with
recombinant AREG.
The present ﬁnding that HIF2-alpha regulates AREG func-
tionally is in line with previous studies investigating the tran-
scriptional pathway of AREG induction during hypoxic
conditions. For example, a previous microarray analysis of colon-
derived epithelial cells revealed a hypoxia-dependent increase in
AREG expression23. Similarly, the authors of this study found
that AREG expression was also induced in tissues from mice
exposed to whole animal hypoxia. Interestingly, and consistent
with the present ﬁndings from myocardial ischemia and reper-
fusion injury, this study revealed that AREG induction was
independent of the classic transcriptional response mediated via
HIF1-alpha, but rather indicated an evolutionarily conserved
cAMP response element (CRE) that constitutively binds the CRE
binding protein (CREB) in AREG induction during hypoxia23.
More recent studies from the cancer ﬁeld provide direct evidence
for a functional role of HIF2-alpha in the induction of AREG
expression during conditions of hypoxia via direct binding of
HIF2-alpha to the AREG promoter, and thereby increasing its
transcriptional activity22,43. These studies found that the PHD-
HIF2A-AREG pathway inﬂuences breast cancer progression and
suggest PHD2 as a potential tumor suppressor in breast cancer43.
However, the functional role of HIF2-alpha-dependent induction
of AREG in myocardial ischemia and reperfusion injury has not
been previously examined. Indeed, our ﬁndings implicate the
PHD–HIF2A–AREG pathway in mediating increased ischemia
tolerance of the myocardium.
The present studies provide pharmacologic evidence that
AREG-mediated cardioprotection involves the growth factor
receptor ERBB1 receptor. Speciﬁc inhibition28 for the AREG
receptor ERBB1 produced a similar phenotype in mice as genetic
deletion of Areg. Consistent with these ﬁndings, previous studies
had demonstrated that AREG binds to the ERBB1 receptor at a
low afﬁnity, thereby causing constant activation of ERBB144. This
distinguishes AREG from other endogenous ligands for the
ERBB1 receptor. For example, EGF binds to ERBB1 with high
afﬁnity, causing a strong and rapid activation, but it also causes
receptor internalization and subsequent degradation, thereby
terminating its signaling events45. Moreover, several potential
mechanisms could inﬂuence how the
HIF2A–AREG–ErbB1 signaling cascade provides cardioprotec-
tion. Previous studies have found a link between ErbB1 signaling
and the inhibition of apoptosis via activation of “survival kina-
ses”46. For example the ErbB1/ErbB2 heterodimer was found to
activate AKT, which in turn blocks p53—a master regulator of
apoptosis47. In the present study, AREG expression during
myocardial ischemia, exogenous AREG administration or Hif2a
expression, and HIF2-alpha stabilization all increased the acti-
vated form of AKT. This suggests that AKT activation in cardi-
omyocytes upon ischemia–reperfusion is executed by HIF2-alpha
and AREG. Indeed, previous studies found a dominant role of
AKT activation in ischemic preconditioning48. Since Hif2aloxP/
loxPMyosin-Cre+ undergo ischemic preconditioning, whereas
Hif1aloxP/loxPMyosin-Cre+ do not, we consider that AKT activa-
tion in cardiomyocytes during ischemia preconditioning is driven
by HIF1-alpha. Independent of AKT activation, ERBB1 reduces
apoptosis via inhibition of caspase-3 and caspase-9 activity49.
However, other studies found that apoptosis contributes to
myocardial injury after days or maybe weeks50. In the acute
setting, such as used in the present study, necrosis mainly
determines infarct sizes and the inﬂuence of apoptosis to myo-
cardial injury is considered rather limited51. Thus, we believe that
in our study, the anti-apoptotic effect of AREG–ERBB1 signaling
only has a minor impact on infarct sizes. Other studies have
indicated that AREG signaling dampens acute inﬂammation,
such as occurs in the context of myocardial ischemia and
reperfusion injury52,53. For example in a model of skeletal muscle
injury, regulatory T cells (Tregs) strongly upregulate AREG, while
treatment with recombinant AREG enhances muscle repair after
injury54 via suppressive Tregs. Other studies suggest that ERBB1
receptor activation promotes the glycolytic capacity, and thereby
provide optimization of cellular metabolism during conditions of
limited oxygen availability—such as occurs during myocardial
ischemia52,53,55
In patients with IHD we found a strong induction of AREG
protein levels. This is consistent with a previous microarray study
showing a 16-fold increase of AREG transcript levels and a 3-fold
increase in protein expression in patients undergoing coronary
bypass surgery56. In view of the present ﬁndings, the AREG
transcript and protein increase during bypass surgery is likely
caused by stabilization of HIF2-alpha protein levels, and could
reﬂect an endogenous protective pathway. Indeed, in the present
studies, treatment with recombinant AREG provides robust car-
dioprotection from ischemia and reperfusion injury (see Fig. 7).
Together, these ﬁndings suggest that pharmacologic HIF activa-
tors (particularly for HIF2-alpha) or treatment with recombinant
AREG could be used to prophylactically treat cardiac surgery
patients to enhance myocardial ischemia tolerance, and thereby
improve outcomes of these major surgical interventions. Simi-
larly, patients at risk for myocardial injury could receive such a
treatment approach.
Taken together, the present studies identify a previously
un-identiﬁed role for myocyte-speciﬁc HIF2-alpha in protection
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from myocardial ischemia and reperfusion injury. Extensions of
these ﬁndings suggest HIF2A-dependent induction of AREG in
cardioprotection from ischemia, and implicate pharmacologic
strategies that stabilize HIFs or promote AREG signaling in
cardioprotection from ischemia and reperfusion injury.
Methods
Cell culture and hypoxia. HCM were purchased from Sciencell Inc. (Carlsbad,
CA). ScienCell Inc. guarantees that cells are free of mycoplasma contamination.
Cells were cultured according to the manufacturer’s instructions and then
transferred into a humidiﬁed hypoxia chamber containing 1% oxygen
(Coy LaboratoryProducts).
Knockdown of HIF1A and HIF2A in vitro. Stable cell cultures with decreased
HIF1A and HIF2A expression were generated by lentiviral-mediated shRNA
expression. Sigma’s MISSION pLKO.1 lentiviral vectors targeting HIF1A had
shRNA sequence of CCGGCCAGTTATGATTGTGAAGTTACTCGAGTAAC
TTCACAATCATAACT GGTTTTT (TRCN0000003809) and HIF2A had a
sequence of CCGGCCATGAGGAGATTCG TGAGAACTCGAGTTCTCA
CGAATCTCCTCATGGTTTTT (TRCN0000003807). For controls, non-targeting
control shRNA (SHC001) was used. HEK293T (American Type Culture
Collection® Inc.) cells were co-transfected with pLK0.1 vectors and packaging
plasmids to produce lentivirus. Filtered supernatants and 8 µg/ml of Polybrene
were used for infection of HCM and cells were selected with puromycin
dihydrochloride (Sigma) (2 µg/ml).
Mice. All animal procedures were performed in an AAALAC-accredited facility in
accordance with the Guide for the Care and Use of Laboratory Animals and
approved by the University of Colorado Denver Institutional Animal Care and Use
Committee. We used male mice with an age of 8- to 16-week-old mice in all
studies. All experiments fulﬁlled the NIH guidelines for use of live animals. To
generate cardiac myocytes speciﬁc-deletion, Myosin-Cre+ (B6.FVB(129)-Tg(Myh6-
cre/Esr1*), Hif1aloxP/loxP (B6.129-Hif1atm3Rsjo/J), and Hif2aloxP/loxP
(Epas1tm1Mcs/J) were purchased from Jackson Laboratory (Bar Harbor, ME) and
crossbred. To induce Cre-recombinase activity, mice underwent tamoxifen treat-
ment for ﬁve consecutive days with 1 mg i.p. per day. Tamoxifen was dissolved in
sterile peanut oil and administered in a volume of 100 μl. Between the last
tamoxifen injection and experimentation were at least 7 days for recovery.
Areg−/− (B6;129-Aregtm1Dle/Mmnc)24 mice were purchased from Mutant
Mouse Regional Resources Centers (Chapel Hill, NC). Areg−/− mice were
maintained using heterozygouse breeding strategy (Areg+/−) to bypass lactation
difﬁculties in younger females. As controls, we used mice with the same genetic
background as Areg−/− (B6,129) mice. Genotyping in all strains used was
performed by GeneTyper Inc. (NY, USA).
Murine model of myocardial ischemia. Mice underwent in situ myocardial
ischemia and reperfusion injury as described previously57,58. In short, we used
sodium pentobarbital to induce and maintain anesthesia. For induction we
administered sodium pentobarbital in a dose of 70 mg/kg i.p., to maintain anes-
thesia in a dose of 10 mg/kg/h i.p.. The mice rested on a temperature-controlled
heated table (RT, Effenberg, Munich, Germany) and were mechanically ventilated
with a pressure-controlled ventilation mode (ventilator settings: inspiratory pres-
sure 10 mbar, frequency 110 breaths/min, positive end-expiratory pressure of 5
mbar, FiO2 = 0.4). After thoracotomy, we visualized the left coronary artery (LCA),
placed an 8.0 nylon suture (Prolene, Ethicon, Norderstedt, Germany) around the
vessel, and connected hanging weights to each end of the suture to occlude the
LCA. We conﬁrmed successful occlusion by color change of the vessel (from light
red to dark violet). In addition, the coloration of the myocardium supplied by the
LCA changed from bright red to pale and an ST-elevation on the connected EKG
was visible. After 60 min of ischemia, the weights were taken off and reperfusion
occurred. This was conﬁrmed by reversal of the color changes of vessel and tissue
described above. In a subset of experiments, mice underwent ischemic pre-
conditioning as described previously59. In short, ischemic preconditioning repre-
sents an experimental strategy, where short non-lethal episodes of myocardial
ischemia result in cardioprotection. Surgical preparation was performed as
described above. Subsequently, we performed four cycles of 5 min of ischemia,
followed by 5 min of reperfusion, before 60 min of ischemia and 120 min of
reperfusion were initiated. If the investigator performing the mouse experiment
observed procedural abnormalities (e.g. incomplete ischemia due to collateral
circulation, involuntary ischemic preconditioning), animals were excluded from
analysis. The investigator was not blinded to genotype and treatment. After 120
min of reperfusion, we determined the infarct sizes by calculating the percentage of
myocardium that underwent infarction compared to the AAR using the double
staining technique with Evan’s blue and triphenyltetrazolium chloride (TTC).
Here, we permanently occluded the suture, followed by injection of Evan’s blue
until the dye was visible in the cardiac veins. The heart was then excised and sliced
into eight slices, 0.5 mm thickness each using a heart matrix (Roboz, Inc.). The
slices were incubated in a TTC at 37 °C for 15 min and then transferred into
formalin for ﬁxation overnight. One day after the experiment, the heart slices were
put between a histology slide, with a clamp on each side and photograph with a
digital camera. Then, AR and the infarct size were determined by planimetry using
the ImageJ (National Institutes of Health). The infarct sizes were determined, using
the following formula: infarct size = sizes of infarct/size area-at-risk × 100. We have
previously described the details of this technique58,59.
Microarray analysis. Myosin-Cre+ and Hif2aloxP/loxPMyosin-Cre+ were used for
microarray analysis to proﬁle the transcriptional response 45 min ischemia and
120 min reperfusion. We used untreated littermates of the same genotype as
baseline control animals. Unpooled RNA, isolated from heart tissue using four of
four animals per group, was proﬁled on Agilent-014868 Whole Mouse Genome
Microarray 4x44K arrays (G4122F; Agilent Technologies, Palo Alto). Array data
were normalized using quantile normalization and statistical analysis performed
using two-factor ANOVA (treatment and genotype) in the Partek Genomics Suite
(Partek Inc., St Louis, MO). Benjamini–Hochberg false discovery rate (FDR) was
used to control for multiple comparisons. Molecules from the dataset that met the
fold change cutoff of 2 and 5% FDR were included in the subsequent analysis.
Myocardial ischemia–reperfusion largely inﬂuenced the gene expression in both
genotypes. To identify Hif2a-regulated genes, we focused on the difference between
the two genotypes after myocardial IR injury using the formula: [(Myosin-Cre
+myocardial IR −Myosin-Cre+myocardial Control) – (Hif2aloxP/loxPMyosin-Cre+myocardial
IR −Hif2aloxP/loxPMyosin-Cre+Control)]. Fisher’s exact test was used to calculate
a p-value determining the probability that the association between the genes
in the dataset is explained by chance alone. Array data have been deposited at
http://www.ncbi.nlm.nih.gov/geo/ (accession number GSE67308).
Human cardiac tissues. In proof of principle studies, AREG protein levels were
measured in human cardiac tissues. Collection and use of these samples was
approved by the Colorado Multiple Institutional Review Board (COMIRB). Prior to
use, the collecting institution (Division of Cardiology, Department of Medicine,
University of Colorado Denver, Aurora, Colorado, USA) de-identiﬁed all heart
samples. We obtained these, via the “University of Colorado–Division of Cardi-
ology Biobank”14. Control cardiac tissues were derived from the left ventricle of
healthy hearts considered for transplantation, but could not be transplanted into a
recipient due to logistic or other reasons. In case of the nonfailing donor hearts, the
family/next of kin gave permission for organ/tissue donation for purposes of
transplantation and research. Ischemic cardiac tissue was obtained from the left
ventricle of patients with ischemic cardiomyopathy, in whom the hearts were
explanted during the process of orthotropic heart transplantation.
Transcriptional analysis. Primer set (sense sequence and antisense sequence,
respectively) for murine Amphiregulin was as following: Areg (Qiagen, Cat#
QT00112217); in case of human cell samples the following primer sets were used:
AREG (Qiagen, Cat# QT02450469); HIF1A (Qiagen, Cat# QT00083664); HIF2A
(Qiagen, Cat# QT00069587). Each target sequence was ampliﬁed using increasing
numbers of cycles of 94 °C for 1 min, 58 °C for 0.5 min, 72 °C for 1 min. β-actin
mRNA (Murine: Qiagen Cat# QT00095242; human: Qiagen, Cat# QT01680476)
was ampliﬁed in identical reactions to control for the amount of starting template.
Levels and fold change in mRNA were determined using the Pfafﬂ method60.
Immunoblotting experiments. To measure Hif1a, Hif2a, Areg, total AKT, or
phosphorylated AKT protein content in the post-ischemic murine myocardium, we
euthanized the animals after 60 min of myocardial ischemia and 120 min reper-
fusion. Subsequently, we ﬂushed the circulation via an arterial catheter with
ice-cold normal saline solution, identiﬁed the myocardial tissue that underwent
ischemia and immediately shock frozen this section of the heart in liquid nitrogen.
For immunoblotting studies, murine or human tissues samples were homogenized
and lysed for 10 min in ice-cold lysis buffer (150 mM NaCl, 25 mM Tris, pH 8.0, 5
mM EDTA, 2% Triton X-100, and 10% mammalian tissue protease inhibitor
cocktail; Sigma-Aldrich). For immunoblotting studies in HCM, we lysed the cells in
5× PAGE buffer, centrifuged the cell suspension at 14,000g to remove cell debris,
and discarded the pellet. Proteins were solubilized in reducing Laemmli sample
buffer and heated to 90 °C for 5 min. Samples were subsequently resolved on a 12%
polyacrylamide gel and transferred to nitrocellulose membranes. The membranes
were blocked for 1 h at room temperature in phosphate-buffered saline (PBS)
supplemented with 0.2% Tween 20 and 4% bovine serum albumin. The antibody to
detect human HIF1a was purchased BD transduction laboratories (clone 54/HIF-
1a; catalog-# 610958). From Novus Biologicals we purchased antibodies to detect
murine Hif1a (clone H1alpha67; catalog-# NB100-105) or Hif2a (clone ep190b;
catalog-# NB100-132). Antibodies were purchased from Santa Cruz Biotechnology
to blot for human AREG or murine Areg (clone G-4; catalog-# sc-74501). From
Cell Signal Technology, we purchased an antibody to detect total Akt (clone 40D4;
catalog-# 2920) and phosphorylated Akt (clone D25E6; catalog-# 13038). The anti-
actin antibody (clone JLA20; catalog-# CP01) was purchased from EMD Millipore.
The membranes were incubated with the primary antibody in 10 μg/ml (dilution
1:1000) overnight at room temperature, followed by 10-min washes in PBS. The
membranes were then incubated in 1:5000 goat anti-mouse horseradish peroxidase.
The wash was repeated, and proteins were detected by enhanced
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03105-2 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:816 |DOI: 10.1038/s41467-018-03105-2 |www.nature.com/naturecommunications 11
chemiluminescence. Densitometry was performed using ImageJ 1.51J8 as descri-
bed61. Full gel scans of all western blots presented in the ﬁgure can be found in the
supplementary ﬁgures (Supplementary Figs. 1–6).
Recombinant murine Areg treatment. Carrier-free, recombinant mouse
Amphiregulin protein (Areg) was purchased from R&D Systems (Minneapolis,
MN). In short, Amphiregulin was dissolved in 0.9% NaCl solution and 10 µg were
administered over 15 min by a syringe pump connected to an indwelling carotid
artery catheter. When the injection was complete, we began the in situ myocardial
ischemia.
AG1478 treatment. The ErbB1 inhibitor AG1478 was purchased from Tocris
(Bristol, United Kingdom). AG1478 was dissolved in 100 mM Captisol (Cydex,
Overland Park, KS) at a concentration of 5 mM as described62. Prior myocardial
ischemia, we administered 200 mmol/l/kg AG1478 over a 15 min period via the
carotid artery catheter connected to a syringe pump28. Then, we continued with
our myocardial ischemia model.
Cetuximab treatment. Cetuximab (Erbitux®) was purchased from Bristol-Myers
Squibb. This monoclonal antibody is speciﬁcally directed against the extracellular
domain of ErbB1, thereby completely blocking signaling through this receptor30.
Immediately prior to myocardial ischemia, we diluted cetuximab in a sterile, iso-
tonic sodium chloride solution and administered 20 mg/kg over a 15 min period
via the carotid artery catheter connected to a syringe pump28. Then, we continued
with myocardial ischemia and reperfusion injury as described above.
Dimethyloxaloylglycine treatment. Dimethyloxaloylglycine (DMOG) was pur-
chased from Sigma-Aldrich. DMOG permeates the cells and inhibits this prolyl-4-
hydroxylase, which upregulates HIFs. As described previously11, mice received 1
mg DMOG via a single intraperitoneal injection 4 h prior to myocardial ischemia
and reperfusion injury—as described above.
Data analysis. Based on previous studies, we performed an a priori sample size
analysis for infarct sizes (standard deviation, SD, 5%) and serum troponin mea-
surements (SD 21 ng/ml)57. We consider a difference biologically relevant, when
infarct sizes differ at least 10% or serum troponin levels at least 45 ng/ml between
control and experimental groups. Based on this, we estimated that we required at
least ﬁve animals per group to detect a statistical signiﬁcant difference with a power
of 80%. All data are presented as mean ± SD. To test for statistical signiﬁcant
differences between two groups, we used the unpaired Student’s t-test. To compare
more than two groups, one-way analysis of variance (ANOVA) with Bonferroni’s
multiple comparison test was used; per journal policy, the degree of freedom and
the F-value are listed in the ﬁgure legends. All comparisons in the current study
underwent two-tailed testing and we considered p< 0.05 to be signiﬁcant. For
samples sizes, outlier analysis (ROUT method) and statistical analyses we used
StatMate® and Prism® (both GraphPad Software Inc.). Statistical analysis was
reviewed by a professional UT Health statistician prior to submission. Sample sizes
are provided in the ﬁgure legends. All authors had full access to and take full
responsibility for the integrity of the data. All authors have read and agree to the
manuscript as written.
Data availability. The array dataset was deposited in GEO under accession code
GSE67308. All relevant data are available from the corresponding author upon
reasonable request.
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